Document text
Principal Investigator: Yuebing Zheng
Organization: UNIVERSITY OF TEXAS AT AUSTIN
Fiscal Year: 2022
Award: $379,952
Funding agency: National Institute of General Medical Sciences
PROJECT SUMMARY
This R01 application is responsive to the NIH initiative PAR-19-253 “Focused Technology Research and Development”.
Assays for measuring receptor-ligand affinity are valuable in many areas of biomedical research. The “gold standard”
surface plasmon resonance assay is limited to recombinant soluble receptors fixed on solid surfaces. The emerging adhesion
frequency assay (AFA) techniques can measure the receptor-ligand affinity on their native cellular membranes. However,
existing AFA methods can neither resolve the non-uniform distribution of receptors on single cells nor measure the rolling
cell adhesion under shear forces. In addition, currentAFAapproaches are generally bulky and low throughput, which require
tedious operation. Recently, we have invented a light-driven microrobot (LDM) platform as a non-invasive, programmable,
and multimodal cell-manipulation technology. Based on this versatile LDM platform, we propose to develop a paradigm-
shift four-dimensional (4D) AFA (i.e., integrated 3D translational AFA and 3D rotational AFA) to overcome these key
obstacles in the existing assays. In this R01 project, we will develop and validate our 4D AFA with the following features:
(1) measuring receptors on their native cell membrane environments, (2) resolving the non-uniformly distributed receptors
on single cells, (3) enabling both translational and rotational AFAs on an integrated platform, (4) investigating cell adhesion
under both shear force and tensile force, and (5) allowing on-chip multiplexed cell adhesion measurements. With such
features, the proposed 4D AFA has the potential to exceed current lab standards, address unmet needs in the field, and
enable high-throughput full profiling of receptor-ligand interactions at sub-cellular resolution. We will validate and improve
the 4D AFA performance using well-studied receptor-ligand pairs with variable affinities. We will further package and
apply the validated assay to investigate the binding of SARS-CoV-2 virus to angiotensin-converting enzyme 2 receptor and
to screen T cells for immunotherapy for cytomegalovirus infection. In this regard, we aim to demonstrate the far-reaching
potential of 4D AFA to enable improved research in areas ranging from clinical immunotherapy to fundamental biology.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D><3-Dimensional><3D><4-dimensional><ACE2><Address><Adhesions><Affinity><Anti-Bacterial Agents><Antibacterial Agents><Antiviral Agents><Antiviral Drugs><Antivirals><Area><Assay><Automation><Bacterial Infections><Benchmarking><Best Practice Analysis><Binding><Bioassay><Biologic Assays><Biological><Biological Assay><Biological Function><Biological Process><Biology><Biomedical Research><Biometrics><Biometry><Biophotonics><Biostatistics><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CMV infection><COVID-19 virus><COVID19 virus><Cell Adhesion><Cell Body><Cell membrane><Cell surface><Cells><Cellular Adhesion><Cellular Membrane><Cellular biology><Clinical><CoV-2><CoV2><Complex><Custom><Cytomegalic Inclusion Disease><Cytomegalovirus Infections><Cytoplasmic Membrane><Devices><Drugs><Endothelium><Environment><Epithelial Cells><Event><Four-dimensional><Frequencies><Glycoproteins><Goals><Gold><Hematopoietic><Histocompatibility Complex><Histocompatibility Complices><Human Figure><Human body><Immune mediated therapy><Immunity><Immunologically Directed Therapy><Immunotherapy><Inclusion Disease><Infection><Investigators><Kinetics><Laser Electromagnetic><Laser Radiation><Lasers><Ligands><Light><MHC Receptor><Major Histocompatibility Complex><Major Histocompatibility Complex Receptor><Major Histocompatibility Complices><Malignant Cell><Maps><Measurement><Measures><Medication><Methods><Microfluidics><Modality><Molecular Interaction><NIH><National Institutes of Health><Optics><Peptides><Performance><Pharmaceutic Preparations><Pharmaceutical Preparations><Photoradiation><Plasma Membrane><Process><Production><Receptor Protein><Recombinants><Research><Research Personnel><Researchers><Resolution><Rotation><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Salivary Gland Virus Disease><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Solid><Stress><Surface><Surface Plasmon Resonance><System><T-Cell Antigen Receptors><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Techniques><Technology><Translations><United States National Institutes of Health><Viral Diseases><Virus><Virus Diseases><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-bacterial><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antibacterial><antiviral compound><antiviral medication><antiviral therapeutic><austin><bacteria infection><bacterial disease><base><biocompatibility><biologic><biomaterial compatibility><cancer cell><cell biology><cell killing><clinical applicability><clinical application><community clinic><coronavirus disease 2019 virus><coronavirus disease-19 virus><design><designing><digital><drug/agent><experiment><experimental research><experimental study><hCoV19><hemopoietic><imaging system><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><insight><medical college><medical schools><microrobot><microrobotics><microsystems><multi-modality><multimodality><multiplex assay><nCoV2><novel><operation><optic imaging><optical><optical imaging><pathogen><plasmalemma><programs><prototype><receptor><recruit><school of medicine><shear stress><simulation><technological research and development><technology research and development><three dimensional><thymus derived lymphocyte><user-friendly><viral infection><virus infection><virus-induced disease><µfluidic>